Pages that link to "Q45249900"
Jump to navigation
Jump to search
The following pages link to Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study (Q45249900):
Displaying 50 items.
- Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients (Q24187385) (← links)
- Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients (Q24244091) (← links)
- Chronic kidney disease mineral and bone disorder in children (Q24642788) (← links)
- Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials (Q26851487) (← links)
- Phosphate control in end-stage renal disease: barriers and opportunities (Q26853372) (← links)
- Regulation of G protein-coupled receptors by allosteric ligands (Q26864384) (← links)
- Recent advances in understanding the extracellular calcium-sensing receptor (Q28069545) (← links)
- Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis (Q28484646) (← links)
- Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis (Q30251450) (← links)
- Allosteric modulation of metabotropic glutamate receptors (Q30448534) (← links)
- End stage renal disease. (Q33446829) (← links)
- Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. (Q33571321) (← links)
- The effects of discontinuing cinacalcet at the time of kidney transplantation (Q33597429) (← links)
- Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease (Q33715510) (← links)
- Calciphylaxis in chronic renal failure: An approach to risk factors (Q33809841) (← links)
- End-stage renal disease (Q33850437) (← links)
- Novel calcium sensing receptor ligands: a patent survey (Q34170892) (← links)
- Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators (Q34271873) (← links)
- The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis (Q34293730) (← links)
- Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism (Q34362759) (← links)
- Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism? (Q34366087) (← links)
- Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders (Q34399823) (← links)
- Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. (Q34567323) (← links)
- Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole (Q34579721) (← links)
- Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study (Q34828835) (← links)
- Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs (Q35026640) (← links)
- Long-term clinical practice experience with cinacalcet for treatment of hypercalcemic hyperparathyroidism after kidney transplantation (Q35226929) (← links)
- Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study (Q35247578) (← links)
- Utilization of parathyroidectomy for secondary hyperparathyroidism in end-stage renal disease (Q35452299) (← links)
- Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism (Q35545384) (← links)
- A new paradigm for the treatment of secondary hyperparathyroidism (Q35573634) (← links)
- Efficacy of early treatment with calcimimetics in combination with reduced doses of vitamin d sterols in dialysis patients (Q35573639) (← links)
- Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics (Q35573647) (← links)
- Potential future uses of calcimimetics in patients with chronic kidney disease (Q35573650) (← links)
- Secondary hyperparathyroidism disease stabilization following calcimimetic therapy (Q35573653) (← links)
- A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM) (Q35682192) (← links)
- Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design (Q35824855) (← links)
- Transient hyperthyroidism after surgery for secondary hyperparathyroidism: a common problem (Q35959149) (← links)
- Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis (Q36121519) (← links)
- Arterial Expression of the Calcium-Sensing Receptor Is Maintained by Physiological Pulsation and Protects against Calcification (Q36122043) (← links)
- Cinacalcet in pediatric and adolescent chronic kidney disease: a single-center experience. (Q36151493) (← links)
- An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects (Q36173980) (← links)
- Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study (Q36199558) (← links)
- Allosteric "beta-blocker" isolated from a DNA-encoded small molecule library (Q36263056) (← links)
- Parathyroidectomy in the calcimimetic era. (Q36284575) (← links)
- Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol (Q36316104) (← links)
- Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. (Q36432849) (← links)
- Keynote review: allosterism in membrane receptors (Q36437496) (← links)
- Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies (Q36567144) (← links)
- Rapid decrease of intact parathyroid hormone could be a predictor of better response to cinacalcet in hemodialysis patients (Q36620322) (← links)